Urovant Sciences, Inc
5281 California Ave, Suite #100
Irvine
California
92617
United States
Tel: +1 949 226 6029
Website: https://urovant.com/
Email: info@urovant.com
About Urovant Sciences, Inc
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions. Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology. At Urovant Sciences, we aim to advance urological patient care through execution of our core values:
Integrity and Compassion
Our commitment to improving patients’ lives begins with personal integrity and how we treat each other.
Bold Innovation
We deliver bold innovation through diversity of thought, openness to new ideas and adaptation to change.
Achievement Through Collaboration
We achieve excellence by uniquely optimizing our collective individual strengths and expertise.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients living with urological conditions.
Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
Every team member has the ability to make an impact to our success.
We are ambitious in our approach to improve outcomes for the patients and healthcare providers we serve. To challenge team members and grow careers, we reward innovation, teamwork, and a winning mindset that produces results.
Urovant Sciences is committed to developing medicines for urological conditions that allow people to live healthier and happier lives.
Our approach is rooted in social responsibility. We are committed to the health and well-being of the patients and healthcare providers we serve, to our employees, and to the communities in which we operate. Urovant Sciences supports policies that improve public health and access to life-impacting therapies regardless of race, ethnicity or ability to pay.
90 articles with Urovant Sciences, Inc
-
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
4/15/2021
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
-
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
4/12/2021
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA ® (vibegron) 75 mg Tablets for Patients with Overactive Bladder Nationwide availability gives healthcare providers and patients a new treatment option
-
The American Urological Association and Urology Care Foundation Unveil New Urology Research Program Supported by $2 Million Donation from Urovant Sciences
4/1/2021
The American Urological Association and Urology Care Foundation announced the launch of a program aimed at fostering diversity and inclusion in urology research, supported by a generous $2 million donation from Urovant Sciences.
-
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
2/11/2021
Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) and urge urinary incontinence (UUI).
-
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
12/23/2020
Urovant Sciences Announces U.S. FDA Approval of GEMTESA ® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences U.S. commercial launch planned in late-Q1 2021 IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urovant Sciences (Nasdaq: UROV) announced today that th
-
The U.S. FDA is plenty busy with COVID-19 vaccine Emergency Use Authorizations this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Here’s a look.
-
Clinical Catch-Up: November 23-27
11/30/2020
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look. -
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
-
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
11/24/2020
Urovant Sciences (Nasdaq: UROV) today reported topline data from the Phase 2a randomized, double blind, placebo-controlled clinical trial evaluating once-daily vibegron 75 mg in women with abdominal pain due to irritable bowel syndrome (IBS) with IBS-D (diarrhea) and IBS-M (mixed IBS).
-
Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
11/19/2020
Urovant Sciences (Nasdaq: UROV) today announced positive efficacy and safety data from the vibegron EMPOWUR long term extension study with patient data over a total exposure of 52 weeks.
-
In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma.
-
Urovant Sciences Enters Into Definitive Agreement for Sumitovant Biopharma to Acquire All Outstanding Shares
11/12/2020
Urovant Sciences Shareholders to Receive $16.25 per share in cash Urovant Special Independent Committee of the Board Unanimously Recommends that all Shareholders Vote in Favor of the Transaction Agreement Represents Confidence in Urovant’s Future Success Transaction expected to be completed in Q1 2021, subject to approval by a majority of minority shareholders IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urova
-
Urovant Sciences to Present at the Jefferies Virtual London Healthcare Conference
11/10/2020
Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 6:10 p.m. GMT (10:10 a.m. PST / 1:10 p.m. EST) on Tuesday, November 17, 2020, at the Jefferies Virtual London Healthcare Conference.
-
Urovant Sciences Reports Second Quarter Fiscal Year 2020 Results
11/2/2020
Urovant Sciences (Nasdaq: UROV) today reported financial results for its fiscal quarter ended September 30, 2020.
-
Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results
10/27/2020
Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the close of U.S. financial markets on Monday, November 2, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s
-
Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
10/7/2020
Urovant Sciences (Nasdaq: UROV) today announced it has entered into a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals Inc. to promote vibegron in the primary care segment upon receiving U.S. Food and Drug Administration (FDA) approval for the drug.
-
Urovant Sciences to Present at the H.C. Wainwright & Co. Annual Global Investment Conference
9/8/2020
Urovant Sciences (Nasdaq: UROV) announced today that president and chief executive officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, September 15, 2020, at the H.C. Wainwright & Co. Annual Global Investment Conference, which is being held virtually. A live, audio webcast for this event will be available on the Investor Relations sectio
-
Urovant Sciences Reports Fiscal First Quarter 2020 Results
8/13/2020
Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access teams and completed enrollment in the Phase 2a study of vibegron for irritable bowel syndrome (IBS) pain.
-
Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results
8/6/2020
Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The con
-
Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
6/18/2020
Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020.